FBRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
24.6M
+9.6%
22.4M
-8.7%
24.6M
+33.7%
18.4M
+58.8%
11.6M
R&D
22.3M
+9.1%
20.5M
-5.8%
21.7M
+43.0%
15.2M
+76.4%
8.6M
SG&A
2.3M
+15.1%
2.0M
-30.5%
2.8M
-10.9%
3.2M
+7.5%
3.0M
Operating Income
-24603000
-9.6%
-22439000
+8.7%
-24571000
-33.7%
-18383000
-58.8%
-11579000
EBITDA
-24583000
-9.6%
-22420000
+8.7%
-24552000
-33.7%
-18366000
-58.8%
-11564000
Net Income
-23331000
-5.4%
-22136000
+10.7%
-24788000
-40.2%
-17682000
-57.2%
-11249000
EPS (Basic)
$-0.97
+21.8%
$-1.24
+10.1%
$-1.38
-39.4%
$-0.99
-3.1%
$-0.96
EPS (Diluted)
$-0.97
+21.8%
$-1.24
+10.1%
$-1.38
-39.4%
$-0.99
-3.1%
$-0.96
Shares (Diluted)
23.8M
+33.4%
17.8M
-0.5%
17.9M
+0.8%
17.8M
+51.5%
11.7M
Forte Biosciences (FBRX) โ€” Financials